Details of the Drug

General Information of Drug (ID: DMAL4G0)

Drug Name
Flurazepam
Synonyms
Dalmadorm; Dalmane; Felison; Felmane; Flunox; Flurazepamum; Insumin; Noctosom; Paxane; Somnol; Stauroderm; Valdorm; Flurazepam HCL; Flurazepam hydrochloride; Dalmadorm (TN); Dalmane (TN); Dalmane-R; Flurazepamum [INN-Latin]; Insumin (TN); Flurazepam (JP15/INN); Flurazepam [INN:BAN:JAN]; Ro-5-6901/3; 2H-1,4-Benzodiazepin-2-one,7-chloro-1-[2-(diethylamino)ethyl]-5-(2-fluorophenyl)-1,3-dihydro-, dihydrochloride; 7-Chloro-1-(2-(diethylamino)ethyl)-5-(2-fluorophenyl)-1,3-dihydro-2H-1,4-benzodiazepin-2-one; 7-Chloro-1-(2-(diethylamino)ethyl)-5-(2-fluorophenyl)-1H-1,4-benzodiazepin-2(3H)-one; 7-Chloro-1-[2-(diethylamino)ethyl]-5-(2-fluorophenyl)-1,3-dihydro-2H-1,4-benzodiazepin-2-one; 7-chloro-1-(2-diethylaminoethyl)-5-(2-fluorophenyl)-3H-1,4-benzodiazepin-2-one
Indication
Disease Entry ICD 11 Status REF
Insomnia 7A00-7A0Z Approved [1], [2]
Therapeutic Class
Hypnotics and Sedatives
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 387.9
Topological Polar Surface Area (xlogp) 3
Rotatable Bond Count (rotbonds) 6
Hydrogen Bond Donor Count (hbonddonor) 0
Hydrogen Bond Acceptor Count (hbondacc) 4
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [3]
Bioavailability
83% of drug becomes completely available to its intended biological destination(s) [4]
Elimination
0.1% of drug is excreted from urine in the unchanged form [3]
Half-life
The concentration or amount of drug in body reduced by one-half in 2.3 hours [5]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 1.10491 micromolar/kg/day [6]
Water Solubility
The ability of drug to dissolve in water is measured as 500 mg/mL [3]
Chemical Identifiers
Formula
C21H23ClFN3O
IUPAC Name
7-chloro-1-[2-(diethylamino)ethyl]-5-(2-fluorophenyl)-3H-1,4-benzodiazepin-2-one
Canonical SMILES
CCN(CC)CCN1C(=O)CN=C(C2=C1C=CC(=C2)Cl)C3=CC=CC=C3F
InChI
InChI=1S/C21H23ClFN3O/c1-3-25(4-2)11-12-26-19-10-9-15(22)13-17(19)21(24-14-20(26)27)16-7-5-6-8-18(16)23/h5-10,13H,3-4,11-12,14H2,1-2H3
InChIKey
SAADBVWGJQAEFS-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
3393
ChEBI ID
CHEBI:5128
CAS Number
17617-23-1
DrugBank ID
DB00690
TTD ID
D08XFV
VARIDT ID
DR00570
INTEDE ID
DR0728
ACDINA ID
D00286

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Translocator protein (TSPO) TTPTXIN TSPO_HUMAN Modulator [7]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Substrate [8]
Cytochrome P450 2A6 (CYP2A6) DEJVYAZ CP2A6_HUMAN Substrate [8]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Flurazepam (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Sodium bicarbonate DMMU6BJ Minor Altered absorption of Flurazepam due to GI dynamics variation caused by Sodium bicarbonate. Acidosis [5C73] [31]
Arn-509 DMT81LZ Moderate Increased metabolism of Flurazepam caused by Arn-509 mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [32]
Oliceridine DM6MDCF Major Additive CNS depression effects by the combination of Flurazepam and Oliceridine. Acute pain [MG31] [33]
Dalfopristin DM4LTKV Moderate Decreased metabolism of Flurazepam caused by Dalfopristin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [34]
Clarithromycin DM4M1SG Moderate Decreased metabolism of Flurazepam caused by Clarithromycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [35]
Troleandomycin DMUZNIG Moderate Decreased metabolism of Flurazepam caused by Troleandomycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [35]
Lapatinib DM3BH1Y Moderate Decreased metabolism of Flurazepam caused by Lapatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [36]
Tucatinib DMBESUA Moderate Decreased metabolism of Flurazepam caused by Tucatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [37]
Dihydrocodeine DMB0FWL Major Additive CNS depression effects by the combination of Flurazepam and Dihydrocodeine. Chronic pain [MG30] [38]
Olopatadine DMKMWQG Moderate Additive CNS depression effects by the combination of Flurazepam and Olopatadine. Conjunctiva disorder [9A60] [39]
Propofol DMB4OLE Moderate Additive cardiorespiratory depression effects by the combination of Flurazepam and Propofol. Corneal disease [9A76-9A78] [40]
Alfentanil DMVO0UB Major Additive CNS depression effects by the combination of Flurazepam and Alfentanil. Corneal disease [9A76-9A78] [33]
Remifentanil DMZTXCH Major Additive CNS depression effects by the combination of Flurazepam and Remifentanil. Corneal disease [9A76-9A78] [33]
Ethanol DMDRQZU Moderate Additive CNS depression effects by the combination of Flurazepam and Ethanol. Cystitis [GC00] [41]
MK-8228 DMOB58Q Moderate Decreased metabolism of Flurazepam caused by MK-8228 mediated inhibition of CYP450 enzyme. Cytomegaloviral disease [1D82] [42]
Nefazodone DM4ZS8M Moderate Decreased metabolism of Flurazepam caused by Nefazodone mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [43]
Esketamine DMVU687 Moderate Additive CNS depression effects by the combination of Flurazepam and Esketamine. Depression [6A70-6A7Z] [44]
SODIUM CITRATE DMHPD2Y Minor Altered absorption of Flurazepam due to GI dynamics variation caused by SODIUM CITRATE. Discovery agent [N.A.] [31]
Cenobamate DMGOVHA Moderate Increased metabolism of Flurazepam caused by Cenobamate mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [45]
Stiripentol DMMSDOY Moderate Decreased metabolism of Flurazepam caused by Stiripentol mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [46]
Fosphenytoin DMOX3LB Moderate Increased metabolism of Flurazepam caused by Fosphenytoin mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [47]
Rufinamide DMWE60C Moderate Increased metabolism of Flurazepam caused by Rufinamide mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [32]
Ethotoin DMXWOCP Moderate Increased metabolism of Flurazepam caused by Ethotoin mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [47]
Tazemetostat DMWP1BH Moderate Increased metabolism of Flurazepam caused by Tazemetostat mediated induction of CYP450 enzyme. Follicular lymphoma [2A80] [48]
Isoniazid DM5JVS3 Moderate Decreased metabolism of Flurazepam caused by Isoniazid mediated inhibition of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [49]
Rifampin DMA8J1G Minor Increased metabolism of Flurazepam caused by Rifampin mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [50]
Fosamprenavir DM4W9B3 Moderate Decreased metabolism of Flurazepam caused by Fosamprenavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [51]
Cobicistat DM6L4H2 Moderate Decreased metabolism of Flurazepam caused by Cobicistat mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [52]
Didanosine DMI2QPE Minor Altered absorption of Flurazepam due to GI dynamics variation caused by Didanosine. Human immunodeficiency virus disease [1C60-1C62] [31]
Amprenavir DMLMXE0 Moderate Decreased metabolism of Flurazepam caused by Amprenavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [51]
Probenecid DMMFWOJ Minor Decreased metabolism of Flurazepam caused by Probenecid. Inborn purine/pyrimidine/nucleotide metabolism error [5C55] [53]
Berotralstat DMWA2DZ Moderate Decreased metabolism of Flurazepam caused by Berotralstat mediated inhibition of CYP450 enzyme. Innate/adaptive immunodeficiency [4A00] [54]
Ceritinib DMB920Z Moderate Decreased metabolism of Flurazepam caused by Ceritinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [32]
PF-06463922 DMKM7EW Moderate Increased metabolism of Flurazepam caused by PF-06463922 mediated induction of CYP450 enzyme. Lung cancer [2C25] [55]
Selpercatinib DMZR15V Moderate Decreased metabolism of Flurazepam caused by Selpercatinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [32]
Idelalisib DM602WT Moderate Decreased metabolism of Flurazepam caused by Idelalisib mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [56]
IPI-145 DMWA24P Moderate Decreased metabolism of Flurazepam caused by IPI-145 mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [57]
Allopregnanolone DMNLHAC Moderate Additive CNS depression effects by the combination of Flurazepam and Allopregnanolone. Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z] [58]
Lasmiditan DMXLVDT Moderate Additive CNS depression effects by the combination of Flurazepam and Lasmiditan. Migraine [8A80] [59]
Flibanserin DM70DTN Moderate Additive CNS depression effects by the combination of Flurazepam and Flibanserin. Mood disorder [6A60-6E23] [60]
Thalidomide DM70BU5 Moderate Additive CNS depression effects by the combination of Flurazepam and Thalidomide. Multiple myeloma [2A83] [61]
Fedratinib DM4ZBK6 Moderate Decreased metabolism of Flurazepam caused by Fedratinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [32]
Nilotinib DM7HXWT Moderate Decreased metabolism of Flurazepam caused by Nilotinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [62]
Modafinil DMYILBE Minor Increased metabolism of Flurazepam caused by Modafinil mediated induction of CYP450 enzyme. Narcolepsy [7A20] [63]
Teduglutide DMYOAKS Moderate Altered absorption of Flurazepam caused by Teduglutide. Neonatal malabsorption syndrome [KB89] [64]
Levomethadyl Acetate DM06HG5 Major Additive CNS depression effects by the combination of Flurazepam and Levomethadyl Acetate. Opioid use disorder [6C43] [38]
Apraclonidine DMO4PVE Moderate Additive CNS depression effects by the combination of Flurazepam and Apraclonidine. Optic nerve disorder [9C40] [65]
Rucaparib DM9PVX8 Moderate Decreased metabolism of Flurazepam caused by Rucaparib mediated inhibition of CYP450 enzyme. Ovarian cancer [2C73] [66]
Oxymorphone DM65AGJ Major Additive CNS depression effects by the combination of Flurazepam and Oxymorphone. Pain [MG30-MG3Z] [33]
Levorphanol DMGS80V Major Additive CNS depression effects by the combination of Flurazepam and Levorphanol. Pain [MG30-MG3Z] [33]
Dezocine DMJDB0Y Major Additive CNS depression effects by the combination of Flurazepam and Dezocine. Pain [MG30-MG3Z] [33]
Nalbuphine DMOSQGU Major Additive CNS depression effects by the combination of Flurazepam and Nalbuphine. Pain [MG30-MG3Z] [33]
Buprenorphine DMPRI8G Major Additive CNS depression effects by the combination of Flurazepam and Buprenorphine. Pain [MG30-MG3Z] [67]
Hydrocodone DMQ2JO5 Major Additive CNS depression effects by the combination of Flurazepam and Hydrocodone. Pain [MG30-MG3Z] [33]
Abametapir DM2RX0I Moderate Decreased metabolism of Flurazepam caused by Abametapir mediated inhibition of CYP450 enzyme. Pediculosis [1G00] [68]
Lefamulin DME6G97 Moderate Decreased metabolism of Flurazepam caused by Lefamulin mediated inhibition of CYP450 enzyme. Pneumonia [CA40] [69]
Lonafarnib DMGM2Z6 Moderate Decreased metabolism of Flurazepam caused by Lonafarnib mediated inhibition of CYP450 enzyme. Premature ageing appearance [LD2B] [70]
Enzalutamide DMGL19D Moderate Increased metabolism of Flurazepam caused by Enzalutamide mediated induction of CYP450 enzyme. Prostate cancer [2C82] [71]
Temsirolimus DMS104F Moderate Increased plasma concentrations of Flurazepam and Temsirolimus due to competitive inhibition of the same metabolic pathway. Renal cell carcinoma [2C90] [72]
Fentanyl DM8WAHT Major Additive CNS depression effects by the combination of Flurazepam and Fentanyl. Sensation disturbance [MB40] [33]
Voxelotor DMCS6M5 Moderate Decreased metabolism of Flurazepam caused by Voxelotor mediated inhibition of CYP450 enzyme. Sickle-cell disorder [3A51] [73]
Telotristat ethyl DMDIYFZ Moderate Increased metabolism of Flurazepam caused by Telotristat ethyl mediated induction of CYP450 enzyme. Small intestine developmental anomaly [DA90] [32]
Larotrectinib DM26CQR Moderate Decreased metabolism of Flurazepam caused by Larotrectinib mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [44]
Armodafinil DMGB035 Minor Increased metabolism of Flurazepam caused by Armodafinil mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [63]
LEE011 DMMX75K Moderate Decreased metabolism of Flurazepam caused by LEE011 mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [74]
Pitolisant DM8RFNJ Moderate Increased metabolism of Flurazepam caused by Pitolisant mediated induction of CYP450 enzyme. Somnolence [MG42] [32]
Tizanidine DMR2IQ4 Moderate Additive CNS depression effects by the combination of Flurazepam and Tizanidine. Tonus and reflex abnormality [MB47] [75]
Sirolimus DMGW1ID Moderate Increased plasma concentrations of Flurazepam and Sirolimus due to competitive inhibition of the same metabolic pathway. Transplant rejection [NE84] [72]
Tacrolimus DMZ7XNQ Moderate Increased plasma concentrations of Flurazepam and Tacrolimus due to competitive inhibition of the same metabolic pathway. Transplant rejection [NE84] [72]
Amiodarone DMUTEX3 Minor Potentiate the pharmacologic effects by the combination of Flurazepam and Amiodarone. Ventricular tachyarrhythmia [BC71] [76]
⏷ Show the Full List of 70 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Allura red AC dye E00338 33258 Colorant
FD&C blue no. 1 E00263 19700 Colorant
FD&C blue no. 2 E00446 2723854 Colorant
Quinoline yellow WS E00309 24671 Colorant
Sodium lauryl sulfate E00464 3423265 Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
FD&C red no. 3 E00629 Not Available Colorant
Ferrosoferric oxide E00231 14789 Colorant
Lactose monohydrate E00393 104938 Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate E00208 11177 lubricant
Propylene glycol E00040 1030 Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
⏷ Show the Full List of 12 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Flurazepam 15 mg capsule 15 mg Oral Capsule Oral
Flurazepam 30 mg capsule 30 mg Oral Capsule Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7188).
2 FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 070344.
3 BDDCS applied to over 900 drugs
4 Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches
5 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
6 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
7 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
8 Is 1-aminobenzotriazole an appropriate in vitro tool as a nonspecific cytochrome P450 inactivator? Drug Metab Dispos. 2009 Jan;37(1):10-3.
9 Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
10 Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
11 Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
12 Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
13 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
14 Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
15 Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
16 The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
17 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
18 Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab Dispos. 2000 Dec;28(12):1457-63.
19 Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
20 Genotoxicity of tamoxifen, tamoxifen epoxide and toremifene in human lymphoblastoid cells containing human cytochrome P450s. Carcinogenesis. 1994 Jan;15(1):5-9.
21 Psychotropic drug interactions with valproate. Clin Neuropharmacol. 2005 Mar-Apr;28(2):96-101.
22 The role of human cytochrome P450 enzymes in the formation of 2-hydroxymetronidazole: CYP2A6 is the high affinity (low Km) catalyst. Drug Metab Dispos. 2013 Sep;41(9):1686-94.
23 Possible involvement of multiple human cytochrome P450 isoforms in the liver metabolism of propofol. Br J Anaesth. 1998 Jun;80(6):788-95.
24 CYP2A6- and CYP2A13-catalyzed metabolism of the nicotine delta-5'(1')iminium ion. J Pharmacol Exp Ther. 2012 Nov;343(2):307-15.
25 Translocator protein (18 kDa) mediates the pro-growth effects of diazepam on Ehrlich tumor cells in vivo. Eur J Pharmacol. 2010 Jan 25;626(2-3):131-8.
26 Comparison of five benzodiazepine-receptor agonists on buprenorphine-induced mu-opioid receptor regulation. J Pharmacol Sci. 2009 May;110(1):36-46.
27 Effects of the combination of metyrapone and oxazepam on cocaine and food self-administration in rats. Pharmacol Biochem Behav. 2008 Nov;91(1):181-9.
28 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2879).
29 Effects of benzodiazepines and non-benzodiazepine compounds on the GABA-induced response in frog isolated sensory neurones. Br J Pharmacol. 1989 Nov;98(3):735-40.
30 New hypnotics: perspectives from sleep physiology. Vertex. 2007 Jul-Aug;18(74):294-9.
31 Chun AH, Carrigan PJ, Hoffman DJ, Kershner RP, Stuart JD "Effect of antacids on absorption of clorazepate." Clin Pharmacol Ther 22 (1977): 329-35. [PMID: 19188]
32 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
33 US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines requires its strongest warning.".
34 Product Information. Synercid (dalfopristin-quinupristin) Rhone-Poulenc Rorer, Collegeville, PA.
35 Amsden GW "Macrolides versus azalides: a drug interaction update." Ann Pharmacother 29 (1995): 906-17. [PMID: 8547740]
36 Product Information. Tykerb (lapatinib). Novartis Pharmaceuticals, East Hanover, NJ.
37 Product Information. Tukysa (tucatinib). Seattle Genetics Inc, Bothell, WA.
38 US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines requires its strongest warning.".
39 Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7. [PMID: 3725002]
40 Gill SS, Wright EM, Reilly CS "Pharmacokinetic interaction of propofol and fentanyl: single bolus injection study." Br J Anaesth 65 (1990): 760-5. [PMID: 2265045]
41 Divoll M, Greenblatt DJ, Lacasse Y, Shader RI "Benzodiazepine overdosage: plasma concentrations and clinical outcome." Psychopharmacology (Berl) 73 (1981): 381-3. [PMID: 6789361]
42 Product Information. Prevymis (letermovir). Merck & Company Inc, Whitehouse Station, NJ.
43 Barbhaiya RH, Shukla UA, Kroboth PD, Greene DS "Coadministration of nefazodone and benzodiazepines: 2. a pharmacokinetic interaction study with triazolam." J Clin Psychopharmacol 15 (1995): 320-6. [PMID: 8830062]
44 Cerner Multum, Inc. "Australian Product Information.".
45 Product Information. Xcopri (cenobamate). SK Life Science, Inc., Paramus, NJ.
46 EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports.".
47 Backman JT, Olkkola KT, Ojala M, Laaksovirta H, Neuvonen PJ "Concentrations and effects of oral midazolam are greatly reduced in patients treated with carbamazepine or phenytoin." Epilepsia 37 (1996): 253-7. [PMID: 8598183]
48 Product Information. Tazverik (tazemetostat). Epizyme, Inc, Cambridge, MA.
49 Ochs HR, Greenblatt DJ, Knuchel M "Differential effect of isoniazid on triazolam oxidation and oxazepam conjugation." Br J Clin Pharmacol 16 (1983): 743-6. [PMID: 6140941]
50 Ochs HR, Greenblatt DJ, Roberts GM, Dengler HJ "Diazepam interaction with antituberculosis drugs." Clin Pharmacol Ther 29 (1981): 671-8. [PMID: 7214796]
51 Product Information. Agenerase (amprenavir). Glaxo Wellcome, Research Triangle Pk, NC.
52 Product Information. Stribild (cobicistat/elvitegravir/emtricitabine/tenofov). Gilead Sciences, Foster City, CA.
53 Abernethy DR, Greenblatt DJ, Ameer B, Shader RI "Probenecid impairment of acetaminophen and lorazepam clearance: direct inhibition of ether glucuronide formation." J Pharmacol Exp Ther 234 (1985): 345-9. [PMID: 4020675]
54 Product Information. Orladeyo (berotralstat). BioCryst Pharmaceuticals Inc, Durham, NC.
55 Product Information. Lorbrena (lorlatinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
56 Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
57 Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA.
58 Product Information. Zulresso (brexanolone). Sage Therapeutics, Inc., Cambridge, MA.
59 Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
60 Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
61 Product Information. Thalomid (thalidomide). Celgene Corporation, Warren, NJ.
62 Product Information. Tasigna (nilotinib). Novartis Pharmaceuticals, East Hanover, NJ.
63 Doherty MM, Charman WN "The mucosa of the small intestine: how clinically relevant as an organ of drug metabolism?" Clin Pharmacokinet 41 (2002): 235-53. [PMID: 11978143]
64 Product Information. Gattex (teduglutide). NPS Pharmaceuticals, Bedminster, NJ.
65 Product Information. Alphagan (brimonidine ophthalmic). Allergan Inc, Irvine, CA.
66 EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".
67 Sekar M, Mimpriss TJ "Buprenorphine, benzodiazepines and prolonged respiratory depression." Anaesthesia 42 (1987): 567-8. [PMID: 3592200]
68 Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
69 Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
70 Product Information. Zokinvy (lonafarnib). Eiger BioPharmaceuticals, Palo Alto, CA.
71 Benoist G, van Oort I, et al "Drug-drug interaction potential in men treated with enzalutamide: Mind the gap." Br J Clin Pharmacol 0 (2017): epub. [PMID: 28881501]
72 Product Information. Prograf (tacrolimus). Fujisawa, Deerfield, IL.
73 Product Information. Oxbryta (voxelotor). Global Blood Therapeutics, Inc., South San Francisco, CA.
74 DSouza DL, Levasseur LM, Nezamis J, Robbins DK, Simms L, Koch KM "Effect of alosetron on the pharmacokinetics of alprazolam." J Clin Pharmacol 41 (2001): 452-4. [PMID: 11304902]
75 Product Information. Zanaflex (tizanidine). Acorda Therapeutics, Hawthorne, NY.
76 Kerin NZ, Aragon E, Faitel K, Frumin H, Rubenfire M "Long-term efficacy and toxicity of high- and low-dose amiodarone regimens." J Clin Pharmacol 29 (1989): 418-23. [PMID: 2661600]